Gold Nanocrystals Show Promise in Treating MS and Parkinson's

Phase 2 clinical trials reveal significant improvements in brain energy metabolites, offering hope for neurodegenerative disease treatments.

Orally administered gold nanocrystals have shown promising results in treating multiple sclerosis (MS) and Parkinson's disease (PD), improving crucial brain energy metabolites.
The treatment, known as CNM-Au8, targets the brain's energy metabolism by enhancing the NAD+/NADH ratio, a key indicator of brain energy capacity.
Participants in the trials experienced a statistically significant increase in the NAD+/NADH ratio, with an average improvement of 10.4% after 12 weeks of treatment.
In Parkinson's disease patients, the treatment led to significant improvements in 'motor experiences of daily living,' suggesting functional benefits.
The research supports advancing to larger phase 3 trials to further test the treatment's efficacy, with ongoing enrollment for participants with progressive MS.